An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

Acute myeloid leukemia (AML) is a hematological malignancy caused by clonal expansion of myeloid progenitor cells. Most patients with AML respond to chemotherapy, but relapses often occur and infer a very poor prognosis. Thirty to thirty-five percent of AMLs carry a four base pair insertion in the n...

Full description

Bibliographic Details
Main Authors: Dyantha I. van der Lee, Georgia Koutsoumpli, Rogier M. Reijmers, M. Willy Honders, Rob C. M. de Jong, Dennis F. G. Remst, Tassilo L. A. Wachsmann, Renate S. Hagedoorn, Kees L. M. C. Franken, Michel G. D. Kester, Karl J. Harber, Lisanne M. Roelofsen, Annemiek M. Schouten, Arend Mulder, Jan W. Drijfhout, Hendrik Veelken, Peter A. van Veelen, Mirjam H. M. Heemskerk, J.H. Frederik Falkenburg, Marieke Griffioen
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cancers
Subjects:
acute myeloid leukemia
neoantigens
cancer immunotherapy
T-cell receptor gene therapy
Online Access:https://www.mdpi.com/2072-6694/13/21/5390

Similar Items

Similar Items